Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Box

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Biorxiv : the Preprint Server for Biology|March 9, 2022
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assaysHelen Box, Shaun H Pennington, Edyta Kijak, et al.
Viruses|August 26, 2023
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in HamstersMegan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, et al.
Nanoscale|April 22, 2021
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injectionJames J Hobson, Alison C Savage, Andrew B Dwyer, et al.
Viruses|January 8, 2025
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden HamstersMegan Neary, Eduardo Gallardo-Toledo, Joanne Sharp, et al.
Clinical Pharmacology and Therapeutics|May 22, 2020
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsUsman Arshad, Henry Pertinez, Helen Box, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith Kr Rajoli, Henry Pertinez, Usman Arshad, et al.
British Journal of Clinical Pharmacology|October 21, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith K R Rajoli, Henry Pertinez, Usman Arshad, et al.
Toxicology and Applied Pharmacology|June 5, 2013
Safety pharmacology--current and emerging conceptsJunnat Hamdam, Swaminathan Sethu, Trevor Smith, et al.
Nature Communications|June 16, 2023
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2Katherine U Gaynor, Marina Vaysburd, Maximilian A J Harman, et al.
Nature|December 5, 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2Teresa Brevini, Mailis Maes, Gwilym J Webb, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Biorxiv : the Preprint Server for Biology|March 9, 2022
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assaysHelen Box, Shaun H Pennington, Edyta Kijak, et al.
Viruses|August 26, 2023
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in HamstersMegan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, et al.
Nanoscale|April 22, 2021
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injectionJames J Hobson, Alison C Savage, Andrew B Dwyer, et al.
Viruses|January 8, 2025
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden HamstersMegan Neary, Eduardo Gallardo-Toledo, Joanne Sharp, et al.
Clinical Pharmacology and Therapeutics|May 22, 2020
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsUsman Arshad, Henry Pertinez, Helen Box, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith Kr Rajoli, Henry Pertinez, Usman Arshad, et al.
British Journal of Clinical Pharmacology|October 21, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith K R Rajoli, Henry Pertinez, Usman Arshad, et al.
Toxicology and Applied Pharmacology|June 5, 2013
Safety pharmacology--current and emerging conceptsJunnat Hamdam, Swaminathan Sethu, Trevor Smith, et al.
Nature Communications|June 16, 2023
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2Katherine U Gaynor, Marina Vaysburd, Maximilian A J Harman, et al.
Nature|December 5, 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2Teresa Brevini, Mailis Maes, Gwilym J Webb, et al.
Pageof 3